LRRK2 and skin cancer: The prevalence of LRRK2 G2019S (the most common genetic determinant of PD) is not increased in patients with melanoma [7], [54], but a recent study showed an almost 3-fold increased risk of non-skin cancers in LRRK2 G2019S mutation carriers [55].